{
    "pmcid": "10213069",
    "qa_pairs": {
        "How were the nanobodies C4 and E3 generated?": [
            "By immunizing alpacas with a human \u03b17-nAChR/mouse 5-HT3A chimera expressed in HEK 293 cells",
            "By immunizing mice with purified \u03b17-nAChR protein",
            "By using a synthetic peptide library targeting \u03b17-nAChR",
            "By immunizing rabbits with \u03b17-nAChR protein fragments"
        ],
        "What is the functional role of the nanobody E3?": [
            "Acts as a positive allosteric modulator (PAM) enhancing acetylcholine-elicited currents",
            "Acts as a silent allosteric modulator (SAM) inhibiting receptor function",
            "Competes with acetylcholine at the orthosteric site",
            "Blocks \u03b1-bungarotoxin binding to the receptor"
        ],
        "What is the primary target of the nanobodies developed in the study?": [
            "\u03b17 nicotinic acetylcholine receptor (\u03b17-nAChR)",
            "\u03b14\u03b22 nicotinic acetylcholine receptor",
            "\u03b13\u03b24 nicotinic acetylcholine receptor",
            "5-HT3A serotonin receptor"
        ],
        "What potential applications do the nanobodies have according to the study?": [
            "Pharmacological and structural investigations, and potential treatments for cognitive disorders",
            "Direct inhibition of viral replication in SARS-CoV-2",
            "Blocking neurotransmitter release in synaptic clefts",
            "Enhancing immune response in autoimmune diseases"
        ],
        "Where do the nanobodies bind on the \u03b17-nAChR?": [
            "An allosteric site on the extracellular domain (ECD)",
            "The orthosteric acetylcholine-binding site",
            "The intracellular domain of the receptor",
            "The transmembrane domain of the receptor"
        ]
    }
}